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p53 loss promotes acute myeloid leukemia
by enabling aberrant self-renewal
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The p53 tumor suppressor limits proliferation in response to cellular stress through several mechanisms. Here, we
test whether the recently described ability of p53 to limit stem cell self-renewal suppresses tumorigenesis in acute
myeloid leukemia (AML), an aggressive cancer in which p53 mutations are associated with drug resistance and
adverse outcome. Our approach combined mosaic mouse models, Cre-lox technology, and in vivo RNAi to disable
p53 and simultaneously activate endogenous KrasG12D—a common AML lesion that promotes proliferation but
not self-renewal. We show that p53 inactivation strongly cooperates with oncogenic KrasG12D to induce aggressive
AML, while both lesions on their own induce T-cell malignancies with long latency. This synergy is based on
a pivotal role of p53 in limiting aberrant self-renewal of myeloid progenitor cells, such that loss of p53 counters the
deleterious effects of oncogenic Kras on these cells and enables them to self-renew indefinitely. Consequently,
myeloid progenitor cells expressing oncogenic Kras and lacking p53 become leukemia-initiating cells, resembling
cancer stem cells capable of maintaining AML in vivo. Our results establish an efficient new strategy for
interrogating oncogene cooperation, and provide strong evidence that the ability of p53 to limit aberrant self-
renewal contributes to its tumor suppressor activity.
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p53 mutations are common in human cancers, and are
frequently associated with aggressive disease courses and
drug resistance (Wattel et al. 1994; Buttitta et al. 1997;
Levine and Oren 2009). Germline p53 mutations pre-
dispose mice and humans to diverse tumors (Malkin et al.
1990; Donehower 1996), and p53 loss cooperates with
a variety of oncogenic lesions—including oncogenic Ras,
deregulated Myc, and loss of Pten—to promote tumori-
genesis in various experimental models (Hermeking and
Eick 1994; Eischen et al. 1999; Johnson et al. 2001; Chen
et al. 2005). In addition, various proteins acting upstream
of or downstream from p53 in its signaling networks
are frequently mutated in human cancers (Bueso-Ramos
et al. 1993; Esteller et al. 2001; Lowe and Sherr 2003;
Brown et al. 2009). Indeed, mutational disruption of the
p53 network may occur in virtually all aggressive end-
stage cancers (Brown et al. 2009).
p53 possesses a range of biological activities that may
contribute to its role in tumor suppression, including its
ability to trigger various cell cycle checkpoints, apopto-
sis, autophagy, differentiation, and cellular senescence
(Meek 2009; Zilfou and Lowe 2009). Moreover, loss of p53
fuels genomic instability to further facilitate tumor
evolution. p53 is best understood for its action in re-
sponse to cellular stress, whereby it elicits one or more of
the above biological responses to limit proliferation. As
an example, oncogenic Ras can trigger replication stress,
which in some instances activates p53 as part of a fail-safe
mechanism that ultimately prevents malignant trans-
formation (Serrano et al. 1997; Bartkova et al. 2006;
Gonzalez et al. 2006). Consequently, p53 loss cooperates
with Ras in many tumor types (Sevignani et al. 1998;
Bardeesy et al. 2001; Johnson et al. 2001; Orsulic et al.
2002; Zuber et al. 2009).
Recent studies have linked p53 to the process of stem
cell self-renewal (TeKippe et al. 2003; Meletis et al. 2006;
Armesilla-Diaz et al. 2009; Liu et al. 2009), which is
defined as a biological process in which a stem cell divides
to generate one (asymmetric division) or two (symmetric
division) daughter stem cells with developmental poten-
tials that are indistinguishable from those of the mother
cell (Molofsky et al. 2004). Normal hematopoietic stem
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cells (HSCs) and mammary stem cells from p53-deficient
mice show increased self-renewal in culture and in mice,
which, in mammary stem cells, result from enhanced
symmetric cell division (Rambhatla et al. 2001; Dumble
et al. 2007; Cicalese et al. 2009; Liu et al. 2009). Moreover,
suppression of p53 or the p53 pathway enhances the
production of induced pluripotent stem (iPS) cells, sug-
gesting that p53 limits the reprogramming of differenti-
ated cells into a self-renewing state (Hong et al. 2009;
Kawamura et al. 2009; Li et al. 2009; Marion et al. 2009;
Utikal et al. 2009). It remains to be determined whether
these effects reflect a physiological role for p53, or are
merely a consequence of stress associated with the exper-
imental manipulation (Krizhanovsky and Lowe 2009).
Nevertheless, the ability of p53 to ‘‘immortalize’’ cells
in culture has long been linked to its role in tumorigen-
esis. Whether or not p53’s function in stem cell biology is
important for its tumor-suppressive role has not been
tested directly.
Acute myeloid leukemia (AML) is a heterogeneous
cancer thought to arise through an accumulation of
mutations that cooperate to deregulate proliferation—
typically by activating Ras signaling pathways—and
impair terminal myeloid differentiation (Gilliland et al.
2004). Both HSCs and more committed myeloid pro-
genitor cells can function as the cellular origin for the
initiation of AML in some circumstances (Passegue et al.
2003). As myeloid progenitors and their differentiated
progeny lack self-renewal capabilities, these cells appar-
ently acquire this ability during the course of leukemia
development. How this occurs has been a topic of much
debate, although fusion proteins involving the mixed-
lineage leukemia (MLL) gene and lesions enhancing Wnt/
b-catenin signaling can confer this capability (Cozzio
et al. 2003; Jamieson et al. 2004; Krivtsov et al. 2006).
Although p53 mutations occur in only 10%–15% of
AMLs at diagnosis, they are associated with the most
aggressive disease courses and drug resistance (Wattel
et al. 1994; Haferlach et al. 2008; Nahi et al. 2008). In-
terestingly, these aggressive clinical traits can be recapit-
ulated in mouse models. For example, our laboratory re-
cently produced a series of mosaic mousemodels of AML,
and applied them to demonstrate that p53 mutations can
confer resistance to the chemotherapeutic agents used to
treat the human disease (Zuber et al. 2009). Furthermore,
we showed that expression ofMLL fusion proteins, which
are also associated with poor prognosis and drug resis-
tance (Schoch et al. 2003), produce some of these aggres-
sive traits by disabling p53 (Zuber et al. 2009). How p53
loss influences AML development remains to be deter-
mined, but may provide insights into the most aggressive
features of this disease.
In this study, we explored the genetic and biological
interactions between oncogenic Kras and p53 in AML.
Expressing oncogenic KrasG12D in the hematopoietic
system drives hyperproliferation and differentiation of
HSCs and myeloid progenitors, resulting in fatal myelo-
proliferative disorders (MPDs) (Braun et al. 2004; Chan
et al. 2004). Unlike MLL fusion oncoproteins, oncogenic
Kras does not enhance the self-renewal of myeloid pro-
genitors. Consequently, KrasG12D-induced MPDs depend
on the involvement of naturally self-renewing HSCs, and
their progression to AML requires secondary lesions in
progenitor populations (Sabnis et al. 2009; Zhang et al.
2009). By exploiting this well-characterized model and
established assays to assess self-renewal capabilities of
normal and leukemic cells, we show that p53 deficiency,
together with oncogenic KrasG12D, provides one mecha-
nism whereby committed myeloid progenitor cells ac-
quire the capacity to self-renew indefinitely and trans-
form into leukemia-initiating cells. Our results therefore
provide new insights into AML biology and p53-mediated
tumor suppression.
Results
A self-excising Cre vector that simultaneously delivers
an shRNA and a GFP reporter
Studies examining the effects of oncogenic Ras in the
myeloid compartment have used bitransgenic mice har-
boring a ‘‘lox-Stop-lox’’ (LSL) Kras allele (Tuveson et al.
2004) and an interferon-responsive Mx1-Cre transgene
(Kuhn et al. 1995). In this system, the oncogenic Kras
allele is knocked into the endogenous locus but kept
silent by the LSL cassette, which can be excised by Cre-
mediated recombination following injection of polyino-
sinic-polycytidylic acid (pIpC). As a consequence of
KrasG12D expression, mice develop a fatal MPD that
initiates in self-renewal-competent HSCs and cannot be
transplanted into syngeneic recipient mice (Braun et al.
2004; Chan et al. 2004; Sabnis et al. 2009; Zhang et al.
2009).
To test the leukemogenic effect of p53 loss in this
model, we began generating compound Mx1-Cre; LSL-
KrasG12D; p53/ mice by intercrossing the individual
mutant strains. Already time-consuming and expensive,
the four-allele cross did not yield sufficient offspring for
studies examining leukemia onset, since mice of the
desired genotype were born at sub-Mendelian ratios and
frequently died shortly after birth due to uncharacterized
causes (data not shown).We also attempted to control p53
deletion through production of Mx1-Cre;LSL-KrasG12D;
p53loxp/loxp mice, in which both activation of Kras and
inactivation of p53 were triggered simultaneously by
Cre-mediated recombination. Shortly after pIpC adminis-
tration, these mice developed complicated phenotypes—
including myeloid hyperplasia, atypical lymphoid hyper-
plasia in thymus and spleen, and histiocytic sarcoma—and
needed to be sacrificed (data not shown).
The difficulties we encountered producing mice har-
boring conditional germline Cre, KrasG12D, and p53
alleles prompted us to explore a more efficient strategy
to examine the effects of p53 inactivation on leukemo-
genesis. Our laboratory has developed methods for mim-
icking tumor suppressor gene loss in mice through stable
RNAi (Hemann et al. 2003, 2004; Xue et al. 2007; Zender
et al. 2008). Therefore, we set out to develop a trans-
plantation-based ‘‘mosaic’’ mouse model in which hema-
topoietic stem/progenitor cells (HSPCs) derived from
Zhao et al.
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LSL-KrasG12Dmice could be transduced with a retrovirus
harboring a shRNA targeting p53.We constructed amurine
stem cell virus (MSCV)-based retroviral vector (LGmCreER)
(see Fig. 1A; Supplemental Fig. S1a) containing a well-
characterized p53 shRNA based on the mir30 design that
efficiently triggers the RNAi machinery and can be
expressed in the same transcript as green fluorescent
protein (GFP) (Dickins et al. 2005; Stegmeier et al. 2005).
To enable coexpression of Cre recombinase from
the same vector, we introduced a tamoxifen-inducible
CreERT2 expressed from a constitutive PGK promoter.
Since long-term Cre exposure can be toxic (Loonstra et al.
2001; Forni et al. 2006), we implemented a novel self-
excising design by flanking the PGK-CreERT2 cassette
with two lox511 sequences, which prevents recombina-
tion with conventional loxP sites in the targeted cells
(Hoess et al. 1986) and retains an intact GFP-shRNA
transgene after Cre excision. Southern blotting of DNA
derived from mouse embryo fibroblasts (MEFs) infected
with virus collected within 24–36 h after packaging cell
transfection revealed that >70% of the integrated pro-
viruses were full-length (Supplemental Fig. S1b). As
predicted, the addition of 4-hydroxytamoxifen (4-OHT)
led to the efficient excision of the PGK-CreERT2 cassette.
Moreover, immunoblotting revealed that cells trans-
duced with the LGshp53CreER vector showed potent
p53 suppression (Supplemental Fig. S1c).
Next, we analyzed the effectiveness of LGmCreER at
excising LSL cassettes. NIH3T3 cells containing a LSL-
LacZ reporter were transduced with LGmCreER and
a non-self-excising MSCV-CreERT2-IRES-GFP vector,
and cell populations were examined in the absence and
presence of 4-OHT (Supplemental Fig. S1d). Each vector
was delivered efficiently into target cells, as assessed by
GFP fluorescence. However, in the absence of 4-OHT,
a high percentage of cells harboring the non-self-excising
vector were b-Gal-positive, suggesting leaky activity of
long terminal repeat (LTR)-driven CreERT2. Moreover,
4-OHT addition induced substantial cell death, presum-
ably owing to Cre toxicity as reported previously (Silver
and Livingston 2001). In contrast, cells transduced with
the LGmCreER construct showed low basal b-Gal activ-
ity, which was induced efficiently by 4-OHT without
signs of toxicity (Supplemental Fig. S1d). Thus, the
LGmCreER vector could deliver a reporter (GFP) and
shRNA to target cells, and, at the same time, induce
Cre-mediated recombination with minimal toxicity.
Loss of p53 cooperates with KrasG12D to promote AML
To test whether p53 suppression cooperates with onco-
genic KrasG12D in promoting AML, we isolated cell
populations enriched for HSPCs from fetal livers of
LSL-KrasG12D embryos and infected these cells with
LGmCreER containing either the p53 shRNA
(LGshp53CreER) or the control empty miR30 cassette
(LGmCreER). Cells were then transplanted into lethally
irradiated syngeneic recipient mice (Fig. 1A). To induce
Cre activity, 4-OHT was either added directly to the
infected HSPCs in vitro or administered to mice by
Figure 1. Activation of endogenous KrasG12D and shRNA-
mediated suppression of p53 cooperate to induce AML. (A)
Schematic of the experimental strategy. Retroviral LGmCreER
is used to cotransduce GFP, a miR30-based shRNA, and 4-OHT-
inducible self-excising CreERT2 into HSPCs isolated from em-
bryonic day 13.5–15.5 fetal livers of LSL-KrasG12D embryos. Cre-
mediated recombination is induced by treatment with 4-OHT
in vitro or in vivo. (B) Representative spleen sonogram and
three-dimensional reconstruction volumetry in recipient mice
of HSPCs of indicated genotypes 6 wk after transplantation.
Numbers indicate average spleen volume and standard devia-
tion in six mice for each genotype. Only KrasG12D-shp53 re-
cipient mice show severe splenomegaly at this preleukemic
stage. (C) Whole-body imaging of representative mice reconsti-
tuted with KrasG12D, shp53, and KrasG12D-shp53 HSPCs. Only
KrasG12D-shp53 mice show strong accumulation of GFP-positive
cells in bones (b), spleen (s), and liver (l). (D) Kaplan-Meier curve
showing the survival of mice reconstituted with KrasG12D-shp53
HSPCs (n = 57) and controls. (**) P = 0.0022 and (***) P < 0.0001
(log-rank test) indicate highly significant survival reduction
compared with recipients of shp53 (n = 12) and KrasG12D (n =
20) control HSPCs, respectively. Secondary transplantation (2nd
tx) curve indicating survival of sublethally irradiated recipient
mice transplanted with KrasG12D-shp53 leukemias (n = 16). (E)
Representative immunophenotyping of KrasG12D-shp53 leuke-
mic bone marrow showing strong infiltration of GFP-positive
cells that are positive for Mac1 and Gr1. (F) Representative
histopathology of KrasG12D-shp53-induced AMLs, including
MPD-like leukemias (panels A–D) and acute myelomonocytic
leukemia (panel E) and AML without maturation (panel F).
(Panel A) Peripheral blood containing elevated numbers of
neutrophilic and monocytic cells. Arrowhead denotes Howell-
Jolly body. (Panel B) Sternal bone marrow filled with maturing
myeloid cells. (Panel C) Spleen with vastly expanded red pulp
filled with erythroid cells (top left) and maturing myeloid
elements (bottom right). (Panel D) Liver with extensive peri-
vascular and sinusoidal hematopoiesis. (Panel E) Bone marrow
cytospin showing blasts and monocytic cells. (Panel F) Bone
marrow cytospin showing immature blast cells. Blood smear
and bone marrow cytospin: Wright-Giemsa; bar, 20 mm. Liver
and spleen: hematoxylin and eosin; bar, 50 mm.
p53 prevents aberrant self-renewal
GENES & DEVELOPMENT 1391
 Cold Spring Harbor Laboratory Press on October 26, 2011 - Published by genesdev.cshlp.orgDownloaded from 
intraperitoneal (i.p.) injection 4 wk after transplantation.
Recipient mice were monitored periodically for signs of
neoplasia, as well as overall morbidity, using sonographic
spleen imaging, whole-body fluorescence imaging, and
blood analysis (white blood cell counts and blood smear
cytology).
As early as 6 wk post-transplantation, and well before
the median onset of blood pathology, mice reconstituted
with KrasG12D-shp53 HSPCs showed pronounced spleno-
megaly (Fig. 1B). At the same time, KrasG12D-shp53 mice
had an accumulation of GFP-positive cells in the bone
marrow, spleen, and liver (Fig. 1C). Eventually, mice
receiving KrasG12D-shp53 HSPCs developed lethal neo-
plasias with amedian survival of 79 d post-transplantation
(n = 45) (Fig. 1D). Bone marrow isolates from animals with
advanced disease were capable of transplanting leukemia
to sublethally irradiated recipient mice (Fig. 1D), indicat-
ing that the neoplasias produced by cells harboring
KrasG12D and p53 shRNAs were bona fide leukemias
rather than an aggressiveMPD (Kogan et al. 2002). Similar
phenotypes were observed regardless of whether 4-OHT
was administered before or after transplantation, although
disease onset and progression was delayed for ;2 wk in
the animals treated post-transplantation (Supplemental
Fig. S2). In contrast, mice carrying wt-shp53 or KrasG12D
alone mainly developed thymic lymphomas, with much
lower penetrance and longer latency compared with
KrasG12D-shp53 leukemias (P < 0.0001 for KrasG12D; P =
0.0022 for wt-shp53) (Fig. 1D; data not shown).
To further characterize these leukemias, we analyzed
leukemic cells and tissues from moribund mice using
flow cytometry and histopathology. GFP-positive leuke-
mic cells were present in the bone marrow, spleen, and
peripheral blood, ranging between 60% and 90% of the
total cell population. Immunophenotyping revealed that
most leukemias were ofmyeloid origin, with themajority
(13 out of 14) consisting of cells expressing Mac1 and Gr1
(Fig. 1E; data not shown). In ;40% of cases (nine out of
22), leukemic mice also had enlarged thymi that were
infiltrated with GFP+/Thy1+ lymphoblasts reminiscent of
concomitant thymic lymphoma. Leukemic mice dis-
played elevated white blood cell counts and signs of
severe anemia (Fig. 1F, panel A). In all cases, the spleens
were massively enlarged and harbored extensive extra-
medullary hematopoiesis and infiltration of myelomono-
cytic cells (Fig. 1F, panel C), while enlarged livers showed
extensive perivascular and sinusoidal leukemia infil-
trates (Fig. 1F, panel D). Approximately two-thirds of
these animals showed MPD-like myeloid leukemias
composed of mature neutrophilic and monocytic cells
and <20% blasts (Fig. 1F, panels A–D), while the other
third presented with either myelomonocytic AML (Fig.
1F, panel E) or AML without maturation (Fig. 1F, panel F;
Kogan et al. 2002). In contrast, recipients of HSPCs
harboring shp53 or KrasG12D as a single lesion developed
late-onset T-cell lymphomas, recapitulating the typical
disease phenotype in p53-null mice (Donehower et al.
1992) and the predominant malignancy in transplant
recipients of pIpC-treated Mx1-Cre;LSL-KrasG12D bone
marrow (Sabnis et al. 2009; Zhang et al. 2009). Hence,
KrasG12D and p53 loss cooperate in the hematopoietic
compartment to induce aggressive AML, and thereby bias
transformation toward the myeloid lineage.
We confirmed activation of KrasG12D and suppression
of p53 using a variety of molecular approaches. First,
using an optimized PCR strategy that enables detection
of rare LSL recombination events in small subpopulations
(Supplemental Fig. S3), we documented excision of the
LSL cassette in peripheral blood of KrasG12D-shp53 re-
cipient mice 7 d after 4-OHT treatment (Fig. 2A, top
panel), and in leukemic cells from multiple recipient
mice (Fig. 2A, bottom panel). Second, we used flow
cytometry (Van Meter et al. 2007) to quantify the
intracellular phosphorylation of various Ras effectors.
Oncogenic Ras aberrantly activates kinase effector path-
ways, which can be assayed by measuring phosphoryla-
tion of Erk1/2 and S6: Accordingly, KrasG12D-shp53
leukemias consistently displayed a substantial elevation
of basal p-Erk1/2 and p-S6 levels in comparisonwith wild-
type bone marrow in both bulk and core progenitor cells
(LincKit+) (Fig. 2C,D; data not shown). In many cases,
stimulation by GM-CSF, a growth factor involved in
normal myeloid cell proliferation, did not further en-
hance p-Erk1/2 levels, indicating that the Raf/Mek/Erk
Figure 2. Molecular characterization of KrasG12D-shp53-in-
duced AML. (A) PCR analysis to verify Cre-mediated recombi-
nation of the LSL cassette. (Top panel) Two-step PCR in
peripheral blood of a representative KrasG12D-shp53 HSPC re-
cipient mouse before and 5 d after 4-OHT treatment in vivo and
after leukemia onset in bone marrow (bm) and spleen (spl).
Recombination is indicated by the appearance of a 749-bp band
after the first (I), and a 249-bp band after the second (II) PCR.
(Bottom panel) LSL-KrasG12D recombination in leukemic mice
(1–5) analyzed in bone marrow and spleen (left and right lane in
each sample, respectively). (nc) Negative control. (B) Western
blotting of p53 in wild-type bone marrow, Arf/, and p53/
MLL/ENL-induced control leukemias and three independent
KrasG12D-shp53 AMLs (#1, #2, and #3) without () or with (+)
adriamycin (Adr) treatment in vitro. (C) Flow cytometry analy-
sis of intracellular phosphorylated Mapk1/Mapk3 (pErk) and
Rps6 (pS6) in bulk and core (LincKit+) populations of wild-type
bone marrow and KrasG12D-shp53 leukemia. (D) Elevated basal
levels of intracellular phosphorylated Mapk1/Mapk3 (pErk) and
Rps6 (pS6) in multiple independent KrasG12D-shp53 AMLs.
Zhao et al.
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cascade was constitutively activated at saturating levels.
Finally, immunoblotting of total bone marrow lysates
extracted from KrasG12D-shp53 leukemic mice revealed
that p53 was virtually undetectable, even following
ex vivo treatment with the DNA-damaging agent adria-
mycin (Fig. 2B). Taken together, these results demon-
strate that the oncogenic effects of KrasG12D and RNAi-
mediated suppression of p53 strongly cooperate in the
myeloid lineage and promote aggressive AML.
p53 suppression induces oncogenic self-renewal
of KrasG12D-expressing hematopoietic progenitor
cells in vitro
Loss of p53 cooperates with oncogenic Ras to promote
transformation in many tissue types, although the bi-
ological basis for these genetic interactions has been
controversial and may be context-dependent (Tuveson
et al. 2004; Collado et al. 2005). The fact that KrasG12D
expression and p53 deficiency synergize to promote AML,
while neither mutation gives rise to this disease as a sole
lesion, suggests unique and potent effects of Ras and p53
signaling on the myeloid lineage. Owing to the avail-
ability of well-established assays to study proliferation,
differentiation, and self-renewal capabilities of hemato-
poietic cells, we reasoned that exploring the functional
role of p53 in this model would provide unprecedented
insights into its action as a tumor suppressor.
Normal hematopoiesis involves a cellular hierarchy
whereby HSCs give rise to multipotential progenitors
(MPPs). These cells eventually differentiate into lineage-
restricted common lymphoid progenitors (CLPs) and
common myeloid progenitors (CMPs), which are com-
mitted to terminal differentiation and unable to self-
renew (Chao et al. 2008). Previous studies have demon-
strated that oncogenic Kras drives proliferation and
differentiation of HSCs andmyeloid progenitors, but does
not promote—and, in fact, depends on—self-renewal
capabilities to initiate disease (Sabnis et al. 2009; Zhang
et al. 2009). Hence, mutations that deregulate Ras signal-
ing frequently co-occur and functionally cooperate with
mutations that impair differentiation and endowmyeloid
progenitor cells with an aberrant and unlimited capacity
to self-renew (Alcalay et al. 2003; Cozzio et al. 2003;
Zuber et al. 2009).
To determine how p53 loss—alone or in cooperation
with KrasG12D—influences proliferation, differentiation,
and life span in the myeloid lineage, we transduced wild-
type and LSL-KrasG12D HSPCs with LGshp53CreER or
a control vector (LGshlucCreER, expressing a control
shRNA targeting firefly luciferase), induced Cre recom-
bination by addition of 4-OHT, and subsequently quanti-
fied stem and progenitor compartments, proliferation,
and self-renewal capacity in the resulting genetic con-
texts (wt-shluc, wt-shp53, KrasG12D-shluc, or KrasG12D-
shp53). Of note, transduced cells can be tracked easily
through expression of the GFP reporter in our vector,
which also enables comparisons with untransduced cells
as internal controls. Cell populations that are enriched for
self-renewing HSCs can be readily identified by flow
cytometry using KSL markers (cKit+Sca1+Lin) (Okada
et al. 1992), or, with greater purity, by incorporating
SLAM markers (CD150+CD48KSL) (Kiel et al. 2005).
Non-self-renewing myeloid progenitors can be identified
as LinCkit+Sca-1IL7Ra cells (Akashi et al. 2000). Of
note, the utility of these markers for identifying HSCs in
in vitro culture still remains controversial; thus, all
results were validated further in vivo (see below).
We first analyzed the proliferation (BrdU [59-bromo-
deoxyuridien] incorporation) and overall representation
of GFP-positive HSCs and myeloid progenitors in culture
(Fig. 3A,B). Consistent with previous reports (Van Meter
et al. 2007; Sabnis et al. 2009), we found that acute
KrasG12D activation resulted in a mild increase in BrdU
incorporation in KSL cells (Fig. 3A), while the overall
frequency of HSCs (CD150+CD48KSL) among trans-
duced cells was reduced compared with wild-type con-
trols (Fig. 3B, top panel). Similar results were observed in
cells cultured in STIFA medium (StemSpan serum-free
media containing the growth factors SCF, TPO, IGF-2,
Figure 3. p53 suppression and KrasG12D induce self-renewal of
myeloid progenitor cells in vitro. (A) BrdU incorporation in
transduced mature myeloid cells (MM; Gr1+), myeloid progen-
itors (MP; LincKit+Sca1IL7Ra), and MPP and stem cells
(KSL; LincKit+Sca1+) in indicated genotypes 4 d following
4-OHT-induced activation of KrasG12D. (B) Frequency of GFP+
HSCs (LincKit+Sca1+CD150+CD48) and myeloid progenitors
(MP; LincKit+Sca1IL7Ra) in all transduced (GFP+) HSPCs of
indicated genotypes (color coding as in A) 4 d after activation of
KrasG12D. (C) Methylcellulose colony formation and serial
replating assay of transduced 4-OHT-treated HSPCs of indicated
genotypes. Representative bright-field and GFP fluorescent
images showing colonies formed after the fourth round of
replating. (D) Quantification of GFP+ colonies of indicated
genotypes over six rounds of replating (color coding as in A).
(E) Percentage of GFP+ cells of indicated genotypes at the end of
each round of replating (color coding as in A).
p53 prevents aberrant self-renewal
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FGF-1, and Angptl3), which supports the expansion of
normal HSCs in vitro (Supplemental Fig. S4; CC Zhang
et al. 2006; Akala et al. 2008). These results suggest that
KrasG12D favors proliferation but not self-renewal of
HSCs. In contrast, although consistent with two recent
reports (Akala et al. 2008; Liu et al. 2009), p53 suppression
increased both the proliferation and frequency of HSCs
(Fig. 3A,B, top panel). p53 loss also increased the pro-
liferation and overall frequency of myeloid progenitors in
both the wild-type and KrasG12D background (Fig. 3A,B,
bottom panel). Thus, in addition to its modest effects on
HSCs, p53 loss dramatically promotes the expansion of
the myeloid progenitor compartment independently of
oncogenic Kras activation.
To analyze the impact of oncogenic Kras activation
and/or p53 suppression on self-renewal, we used a well-
established serial replating assay, whereby the life span of
progenitors is assessed by their ability to form colonies
derived from single cells in methylcellulose (Lavau et al.
1997). Normal myeloid progenitors are able to form
colonies in only the first two to three rounds of replating,
and then exhaust their proliferative potential. We plated
5000 GFP+ wt-shluc, wt-shp53, KrasG12D-shluc, and
KrasG12D-shp53 HSPCs in methylcellulose and counted
the number of GFP+ colonies 7 d later. Cells were then
harvested, and the same procedure was repeated.
Consistent with previous reports (Braun et al. 2004;
Chan et al. 2004), wild-type and KrasG12D HSPCs lost
their ability to produce colonies during the fourth round
of replating, indicating that the population had exhausted
its progenitor compartment (Fig. 3C,D). Conversely, wt-
shp53 cells showed a steady enrichment of GFP+ cells
over time (Fig. 3E), and modest enhancement in their
colony-forming and replating ability (Fig. 3C,D; see also
Liu et al. 2009). In marked contrast, KrasG12D-shp53 cells
continued forming numerous robust GFP+ colonies
through six rounds of replating, after which the experi-
ments were terminated (Fig. 3C,D). Outgrown KrasG12D-
shp53 colonies after the fourth round of replating con-
tained myeloid progenitors and MPPs that were all
positive for GFP (data not shown). Furthermore, cells
recovered from KrasG12D-shp53 colonies were able to
induce aggressive AML and T-cell lymphoma after trans-
plantation into sublethally irradiated recipient mice (data
not shown), indicating they were enriched for leukemia-
initiating cells. Taken together, these in vitro results
indicate that loss of p53 enhances proliferation of mye-
loid progenitor cells, and, in combination with oncogenic
Kras, enables these cells to continually self-renew.
p53 loss enables KrasG12D-expressing myeloid
progenitors to become leukemia-initiating cells
In contrast to KrasG12D-induced MPD, which depends on
the involvement of naturally self-renewing HSCs (Sabnis
et al. 2009; Zhang et al. 2009), our in vitro studies indicate
that self-renewal capabilities can be acquired de novo
in myeloid progenitors lacking p53. To determine how
loss of p53 and activation of oncogenic Kras affect my-
eloid progenitors in vivo, we transduced both wild-type
and LSL-KrasG12D HSPCs with LGshlucCreER or
LGshp53CreER and transplanted these cells into lethally
irradiated recipients. Transduction efficiencies were con-
sistently ;40% (data not shown), such that HSPCs of all
genotypes contained a comparable fraction of nontrans-
duced (GFP) cells as an internal wild-type control
population. In order to bypass deleterious effects of Ras
activation on engraftment (Sabnis et al. 2009), KrasG12D
expression was triggered upon host reconstitution by
4-OHT treatment. To determine the relative competition
between cells harboring activated Kras and/or p53 knock-
down (GFP+) and nontransduced internal controls, we
analyzed the frequency of GFP+ cells in total bone mar-
row and the myeloid progenitor and HSC subcompart-
ments 3 wk later. In parallel, we analyzed the frequency
of myeloid progenitors and HSCs among all GFP+ cells,
which reflects the relative growth potential of cells
within the total transduced population.
Compared with bone marrow from mice transplanted
with wt-shluc HSPCs, recipients of KrasG12D-shluc
HSPCs showed a consistent, although not significant,
decrease in GFP+ cells in bone marrow, myeloid pro-
genitors, and HSCs (see Fig. 4A for a representative flow
cytometry profile, and B for quantification), indicating
that KrasG12D expression did not confer a competitive
advantage to these cells in vivo. Consistent with previous
findings in the Mx1-Cre;LSL-Kras MPD model (Van
Meter et al. 2007) and our in vitro results, we observed
a reduced frequency of myeloid progenitors (Fig. 4C) and
HSCs (Fig. 4D) among all GFP+ cells. In contrast, in-
dependently of KrasG12D, shp53-expressing cells were
strongly enriched in total bone marrow, HSCs, and my-
eloid progenitors (Fig. 4A,B), indicating that p53 suppres-
sion conferred a selective advantage in these compart-
ments in vivo.
In the context of oncogenic KrasG12D, p53 had opposing
effects on the size of HSC and myeloid progenitors
compartments: While p53 suppression prevented the
KrasG12D-induced depletion of myeloid progenitors to
levels at or above those occurring in wt-shluc controls
(Fig. 4C), the percentage of GFP+ HSCs was unchanged or
even further reduced compared with KrasG12D alone (Fig.
4D). Moreover, bone marrow from mice with advanced
leukemia consistently showed a strong enrichment of
GFP+ cells in the myeloid progenitor compartment, while
HSCs were almost exclusively GFP-negative (Fig. 5A).
This suggests that HSCs might be dispensable for main-
taining KrasG12D-shp53 AML in vivo. These results imply
that intact p53 limits the expansion of normal and Kras
mutant myeloid progenitors in vivo, while p53 loss al-
lows oncogenic Kras to trigger aberrant proliferation of
this compartment.
To rigorously interrogate these ‘‘rescued’’ myeloid pro-
genitors for aberrant self-renewal capabilities, and to
assay their ability to initiate Kras-shp53-induced AML,
we purified LinCkit+Sca-1IL7Ra cells from preleuke-
mic (3 wk post-4-OHT treatment) and leukemic mice in
two consecutive rounds of fluorescence-activated cell
sorting (FACS). GFP+ myeloid progenitors (2000–5000 per
mouse) were injected with 200,000 wild-type syngeneic
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helper cells into lethally irradiated recipient mice (see
Fig. 5B for schematic overview). While all mice receiving
Kras-shluc control cells remained healthy, those receiv-
ing Kras-shp53myeloid progenitors rapidly succumbed to
AML (Fig. 5C). Interestingly, the resulting leukemias
displayed immunophenotypes resembling the primary
AMLs described above (GFP+Mac1+Gr1+) (Fig. 5D,E),
while none were accompanied by concomitant thymic
lymphoma (data not shown). Hence, sorted Kras-shp53
myeloid progenitors formed leukemia while maintaining
their differentiation potential. Collectively, these results
indicate that myeloid progenitors with oncogenic Kras
activation and p53 deficiency gain self-renewal capability
in vivo, and can serve as leukemia-initiating cells.
p53 gene deletion recapitulates the effects of p53
knockdown in myeloid progenitors
To rule out the possibility that technical aspects of the
experimental system (such as isolation of fetal liver
HSPCs; methods of Cre delivery, transplantation, and
reconstitution; RNAi off-target effects; etc.) influenced
our observations, we repeated key experiments in an
entirely transgenic setting. To produce the precise genetic
configurations described above, we intercrossedMx1-Cre
(C), LSL-KrasG12D (K), and p53loxp/loxp (P) mice. Mx1-
Cre;LSL-KrasG12D;p53loxp/loxp (CKP) and control (C, CK,
and CP) mice were treated with pIpC to activate KrasG12D
and inactivate p53 (p53D2–10) at 6 wk of age. Seven days
later, we harvested bone marrow from mice of each
genotype to perform colony-forming and serial replating
assays as well as FACS analysis for the frequency of
maturemyeloid cells and stem/progenitor populations. In
addition, myeloid progenitors were isolated by FACS and
Figure 4. p53 suppression expands myeloid progenitors in
vivo and, in concert with endogenous, KrasG12D promotes
leukemogenesis. (A) Representative bone marrow flow cytom-
etry profiles of stem and myeloid progenitor compartments
of mice reconstituted with HSPCs of indicated geno-
types, including conventional Lin/cKit/Sca1 staining (MP;
LincKit+Sca1IL7Ra), KSL (LincKit+Sca1+), SLAM markers
(HSC; LincKit+Sca1+CD150+CD48), and histograms indicat-
ing the percentage of GFP+ cells in myeloid progenitors. (B)
Frequency of GFP+ cells in total bone marrow (all), myeloid
progenitors (MP), and HSCs of mice reconstituted with HSPCs
of indicated genotypes 3 wk after in vivo 4-OHT treatment to
induce KrasG12D (n = 4–5 in each group). (C) Quantification of
GFP+ myeloid progenitors within GFP+ bone marrow cells of
mice reconstituted with HSPCs of indicated genotypes (n = 4–5
in each group). (D) Quantification of GFP+ HSCs within GFP+
bone marrow cells of mice reconstituted with HSPCs of in-
dicated genotypes (n = 4–5 in each group).
Figure 5. KrasG12D-shp53 myeloid progenitor cells induce
AML. (A) Representative bone marrow flow cytometry profiles
of stem and progenitor compartments in KrasG12D-shp53 leuke-
mic mice, including conventional Lin/cKit/Sca1 staining (left
two panels), SLAM markers (middle panel), and a histogram
indicating the percentage of GFP+ in HSCs and myeloid pro-
genitors (right two panels). (B) Schematic overview of genera-
tion, sorting, and secondary transplantation of KrasG12D-shp53
myeloid progenitor cells. (C) Kaplan-Meier curve of lethally
irradiated recipient mice transplanted with 2000–5000 doubly
sorted myeloid progenitor cells isolated from six independent
primary recipients of KrasG12D-shp53 HSPCs (n = 18) and
KrasG12D HSPCs (n = 3). (D) Representative bone marrow flow
cytometry analysis of leukemia induced by transplantation of
KrasG12D-shp53 myeloid progenitors. (Left panel) The bone
marrow is dominated by GFP+ cells, which are predominantly
expressing Mac1 and Gr1. (E) Histopathology analysis of leuke-
mias induced by transplantation of KrasG12D-shp53 myeloid
progenitors. (Panel A) Sternal bone marrow densely packed with
blasts and few maturing myeloid cells (1003). (Panel B) Spleen
with areas predominated by blasts and maturing neutrophils
(1003). (Panel C) liver with invasion of leukemic cells with
differentiation (403). All hematoxylin and eosin-stained. Bars:
403 images, 50 mm; 1003 images, 20 mm.
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assessed for their capacity to initiate leukemia using the
same strategies described above (for overview, see Sup-
plemental Fig. S5).
Precisely paralleling our observations using the retro-
viral HSPC transduction approach, p53D2–10 bone marrow
cells displayed mildly enhanced colony-forming and
replating capacity, while the combination of KrasG12D
and p53D2–10 induced a dramatic increase in colony-
forming and replating capabilities (Fig. 6A,B). Consistent
with published results (Braun et al. 2004; Chan et al.
2004; Van Meter et al. 2007; Sabnis et al. 2009) and
observations from our retroviral system, bone marrow
analysis showed that KrasG12D expression uniformly
resulted in increased frequency of mature myeloid cells
(Fig. 6C, top) as well as an approximately twofold re-
duction in HSC frequency, which was not rescued but
was aggravated further by loss of p53 (Fig. 6C, bottom).
The frequency of myeloid progenitors in KrasG12D bone
marrow was not reduced at this time point (10 d post-
pIpC) as in fully developed MPD (;50 d post-pIpC) (Van
Meter et al. 2007). However, as in the retroviral system,
combined KrasG12D;p53D2-10 mice showed the most dra-
matic expansion of myeloid progenitors in vivo (Fig. 6C,
middle).
As seen in the retroviral setting, combined occurrence
of oncogenic KrasG12D and loss of p53 enabled myeloid
progenitors to self-renew, as well as to initiate and
propagate leukemia in vivo. Most recipient mice of
KrasG12D;p53D2–10 myeloid progenitors succumbed to
leukemias, with a median survival of 62 d (Fig. 6D), while
all recipients of myeloid progenitors harboring KrasG12D
as a single lesion remained disease-free. Histopathologic
analysis showed a massive mononuclear infiltration in
bone marrow, spleen, and liver, indicating the presence of
leukemia (Fig. 6E; data not shown). In summary, our
observations using a purely transgenic system confirm
biology obtained through our rapid retroviral approach,
and collectively demonstrate that loss of p53 strongly
cooperates with KrasG12D to promote leukemogenesis in
themyeloid lineage by rendering myeloid progenitor cells
capable of indefinite self-renewal.
Discussion
A rapid and versatile approach to study the interplay
of complex mutations in cancer
We used a novel approach that combines RNAi technol-
ogy, Cre-lox-conditional transgenic alleles, and mosaic
mouse cancer models to efficiently study the interplay
between p53 and Ras signaling in AML. Using retrovi-
ral codelivery of a miR30-based shRNA, CreERT2, and
GFP into HSPCs harboring a single Cre-lox-activatable
KrasG12D allele, we rapidly generated compound muta-
tions alongside the relevant control genotypes, and tagged
these modified cells with a fluorescent reporter for easy
tracking and isolation in vitro and in vivo. Our system
minimizes the impact of Cre-mediated toxicity by using
inducible CreERT2 and implementing a new strategy to
excise the Cre transgene as soon as Cre is enzymatically
active. Using conventional germline methods, the gener-
ation of such compound mutant conditions would have
required producing mice harboring five germline alleles
and, hence, many months of crossing to generate suffi-
cient animal numbers. Moreover, unlike strictly trans-
genic systems, the resulting mice are ‘‘mosaics,’’ such
that only a subset of cells in the hematopoietic system
harbor the oncogenic lesions, much as would occur in
human leukemia patients.
Beyond leukemia, our rapid approach can be used in
other mosaic models of cancer (e.g., breast, liver, and
brain). Importantly, the combination of endogenous Cre-
lox conditional knock-in alleles and RNAi provides
a means to model oncogenic alleles that are expressed
Figure 6. Conditional p53 deletion recapitulates the effects of
RNAi-mediated p53 suppression. (A) Methylcellulose cultures
(bright-field images) of bone marrow cells of indicated genotypes
after the third round of replating. Robust CFU-M-, CFU-G-, and
CFU-GM-like colonies are only formed by KrasG12D;p53D2-10
bone marrow cells. (B) Quantification of colony formation in
bone marrow cells of indicated genotypes over four rounds of
replating. (C) Frequency of mature myeloid cells (MM;
Mac1+Gr1+), myeloid progenitors (MP; LincKit+Sca1IL7Ra),
and HSCs (LincKit+Sca1+CD150+CD48) in bone marrow of
mice with indicated genotypes (color coding as in B) 7–10 d after
pIpC treatment (n = 3–5 for each genotype). (D) Kaplan-Meier
curve of lethally irradiated recipient mice transplanted with
2000–5000 myeloid progenitor cells doubly sorted from primary
Mx1-Cre;LSL-KrasG12D;p53loxp/loxp (n = 9) and Mx1-Cre;LSL-
KrasG12D (n = 3) mice. (E) Histopathology analysis of donor
and recipient mice of Mx1-Cre;LSL-KrasG12D;p53loxp/loxp mye-
loid progenitors. (Panel A) Bone marrow (1003) of a donor
mouse at the time of myeloid progenitor isolation (10 d after
pIpC induction of Cre) showing normal mixed hematopoeisis.
(Panels B–D) Bone marrow (1003), spleen (403), and liver
sections (403), respectively, of a myeloid progenitor recipient
mouse showing leukemia infiltrates. All hematoxylin and eosin-
stained. Bars: 403 images, 50 mm; 1003 images, 20 mm.
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at their endogenous loci, thereby eliminating overexpres-
sion artifacts and more accurately mimicking conditions
in human cancers. As a growing number of such ‘‘endog-
enous’’ genetically engineered mice harboring Cre-lox-
inducible alleles (including oncogene mutations, trans-
locations, and deletions) become available (for review, see
Frese and Tuveson 2007), our approach will provide
greater flexibility in using these systems for studying
the interplay of complex mutations in cancer.
Interplay between KrasG12D and loss of p53 in AML
Ras pathway mutations—including activating mutations
in N- and KRAS, as well as other network components
(such as FLT3, KIT, NF1, and PTPN11)—occur in the
majority of human AML cases (Scholl et al. 2008). In
mouse models, some of these lesions act to force both
proliferation and differentiation of HSCs and myeloid
progenitors, leading eventually to the development of
MPD (Braun et al. 2004; Chan et al. 2004). However, Ras
signaling does not override the intrinsic programs that
limit the ability of myeloid cells to self-renew, and,
indeed, may trigger them (Braun et al. 2004; Chan et al.
2004). Consequently, Ras-induced MPDs depend on nat-
urally self-renewing HSCs to initiate disease (Sabnis et al.
2009; Zhang et al. 2009). Studies suggest that progression
to full-blown AML requires the acquisition of one or more
additional lesions that may confer aberrant self-renewal
capabilities to cells within the myeloid lineage. For ex-
ample, fusion proteins involving MLL promote self-
renewal ofmyeloid progenitors (Cozzio et al. 2003; Huntly
et al. 2004) and efficiently cooperate with oncogenic Ras
in leukemogenesis (Zuber et al. 2009). In addition, these
lesions act to potently suppress myeloid differentiation.
Unexpectedly, we found that both shRNA-mediated
suppression and genomic deletion of p53 induced aber-
rant self-renewal in myeloid progenitor cells, which, in
concert with oncogenic Kras, were able to initiate and
propagate AML. Thus, in this system, p53 abrogates the
requirement of HSC involvement for Ras-induced mye-
loid disorders, and enablesmyeloid progenitors to serve as
leukemia-initiating cells. However, in contrast to self-
renewal-promoting fusion proteins capable of inducing
poorly differentiated diseases, p53 loss gives rise to pre-
dominantly differentiated AML. Thus, loss of p53 acts
strictly to promote self-renewal while enabling leukemia
cells to retain their differentiation program, revealing for
the first time that impaired differentiation and self-re-
newal are separable functions during myeloid leukemo-
genesis. Moreover, p53 suppressionmay contribute to the
self-renewing effects of other AML oncogenes, and, con-
sistent with this possibility, MLL fusion proteins can
promote leukemogenesis in part by disabling p53 (Zuber
et al. 2009).
Our analyses confirm previous studies demonstrating
that KrasG12D leads to the proliferation, differentiation,
and, therefore, long-term depletion of HSCs, while loss of
p53 expands this compartment (Akala et al. 2008; Liu
et al. 2009; Sabnis et al. 2009). Surprisingly, p53 suppres-
sion is unable to override the Ras-induced depletion of
HSCs, suggesting that p53 is not a key player protecting
against Ras-induced effects in this compartment. Indeed,
our ability to track Kras-p53shRNA-expressing cells
using a linked GFP reporter revealed that leukemia-
bearing mice harbor few, if any, Kras-shp53-expressing
HSCs (see Figs. 4D, 5A, 6C). Although our data do not rule
out the possibility that HSCs can serve as AML-initiating
cells, they indicate that HSCs are dispensable for Kras-
shp53-mediated leukemogenesis.
In contrast, we found committed myeloid progenitors
to be exquisitely sensitive to p53-mediated tumor sup-
pression in the presence of activated Ras, since the
combination of both lesions strongly promoted the pro-
liferation, subsequent expansion, and aberrant self-
renewal of these cells. Interestingly, the combined acti-
vation of Kras and loss of p53 in multipotent HSPCs
resulted in AML as the dominant disease phenotype,
while bothmutations as single lesions almost exclusively
drive T-cell malignancies in the same experimental
system. While molecular mechanisms underlying the
hypersensitivity of myeloid progenitors to Kras-shp53-
mediated transformation are not understood, it is note-
worthy that p19ARF—a key inducer of p53 in response to
oncogenic Ras (Sherr and McCormick 2002)—is silenced
in HSCs (Park et al. 2003), yet becomes poised to fulfill its
gatekeeper functions as soon as progenitor cells reach
a lineage-committed stage (Williams and Sherr 2008).
Interestingly, preliminary experiments applying our mo-
saic approach showed that combined suppression of
p19Arf and p16Ink4a also promotes leukemogenesis in
concert with KrasG12D (Z Zhao, J Zuber, and SW Lowe,
unpubl.). Further studies will be required to dissect the
role of both genes and their interplay with p53 during
myeloid leukemogenesis.
Prevention of aberrant self-renewal and tumor
suppression by p53
Our studies provide new insights into the tumor-suppres-
sive functions of p53. p53 can be activated in response to
various forms of cellular stress, leading to a broad spec-
trum of cellular responses such as apoptosis, cell cycle
arrest, senescence, or autophagy in a context-dependent
manner (Zilfou and Lowe 2009). The most extensively
studied mechanisms underlying p53’s function as a tu-
mor suppressor involve its ability to trigger two fail-safe
programs—apoptosis and senescence—in response to Ras
activation and other oncogenic stimuli. In the hemato-
poietic system, Ras activation results in hyperprolifera-
tion of stem and progenitor cells. This proliferative burst
is inseparably linked to terminal differentiation, estab-
lishing a barrier to limitless proliferation of Ras mutant
cells. While phenotypic markers may vary, the ability of
Ras to enforce a terminal cell fate program is conceptu-
ally similar to oncogene-induced senescence observed in
fibroblasts and certain epithelial cell types (Serrano et al.
1997; Lin and Lowe 2001). Moreover, our data suggest
that p53 plays an essential role in these myeloid fail-safe
programs by limiting aberrant self-renewal and enforcing
terminal differentiation.
p53 prevents aberrant self-renewal
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p53 has been implicated in limiting self-renewal of
normal HSCs and neuronal stem cells (Meletis et al. 2006;
Zheng et al. 2008; Liu et al. 2009). In normal progenitor
cells, p53 acts as a modulator rather than a sole barrier to
self-renewal: Its inactivation delays, but does not prevent,
the eventual exhaustion of the progenitor compartment.
Our data demonstrate that, in the context of activated
Ras, the presence or absence of p53 becomes a decisive
factor determining between fail-safe elimination and
limitless growth. We show that loss of p53 in myeloid
progenitor cells circumvents the deleterious effects of
Kras activation and establishes aberrant self-renewal,
paving the way for AML development. Although we
cannot rule out that additional functions of p53 contrib-
ute to tumor suppression in this context, the de novo
acquisition of self-renewal in cells that normally lack this
capability could be a key function of p53 mutations in
AML and perhaps other tumor types where a differentia-
tion hierarchy plays a role in disease.
Similar to activated Ras, the BCR-ABL fusion protein
drives proliferation and differentiation of HSCs and
myeloid progenitors, and can initiate an MPD—chronic
myeloid leukemia (CML)—that requires the involvement
of self-renewing HSCs (Huntly et al. 2004; Williams and
Sherr 2008; Schemionek et al. 2010). If untreated, the dis-
ease inevitably progresses to fatal blast crisis (CML-BC),
often resembling AML. Interestingly, the most frequent
secondary alterations in myeloid CML-BC involve p53,
which is mutated in 25%–30% of cases or repressed by
activation of its negative regulator, MDM2 (Calabretta
and Perrotti 2004). Of note, homozygous deletions en-
compassing ARF are a hallmark mutation in lymphoid
CML-BC- and BCR-ABL-positive ALL, and are associated
with poor prognosis (Williams and Sherr 2008). Given the
similarity between KrasG12D and BCR-ABL in their ef-
fects on HSCs and myeloid progenitors, aberrant self-
renewal caused by loss of p53 could explain the high
frequency of p53 mutations in myeloid CML-BC.
Interestingly, loss of the Pten tumor suppressor, which
activates the PI3K pathway downstream from Ras and
can also trigger senescence, depletes the HSC compart-
ment and can induce MPDs (Yilmaz et al. 2006; J Zhang
et al. 2006). In preliminary studies, we applied our
approach to introduce LGshp53CreER into Ptenfl/fl
HSPCs, and saw a strong acceleration of leukemogenesis
resulting from combined loss of p53 and Pten (Z Zhao,
J Zuber, and SW Lowe, unpubl.). Other studies using
standard germline methods noted similar effects (JY Lee
and S Morrison, unpubl.), suggesting that p53 may act
generally in the hematopoietic compartment to limit
self-renewal in response to oncogenic stress.
p53 has long been associated with cellular immortali-
zation in vitro (Jenkins et al. 1984), which is an acquired
property that confers limitless replicative potential and is
considered to be an essential property of cancer cells
(Hanahan and Weinberg 2000). As such, the process of
immortalization may conceptually and mechanistically
overlap with the physiological process of self-renewal.
Although the mechanism whereby p53 loss promotes
immortalization or enhances self-renewal remains elu-
sive, it is noteworthy that p53 can serve as a barrier to
epigenetic reprogramming of somatic cells into pluripo-
tent stem cells (Puzio-Kuter and Levine 2009). Accord-
ingly, loss of p53 might contribute to the formation of
leukemia-initiating cells, which by definition have
maintained or reacquired the capacity for indefinite self-
renewal through accumulated mutations and/or epige-
netic changes (Passegue and Weisman 2005). Such cells
have properties reminiscent of cancer stem cells, which
are considered to be inherently more aggressive and re-
fractory to chemotherapy (Guan and Hogge 2000; Jordan
and Guzman 2004; Holtz et al. 2005). Consequently, our
results suggest a biological explanation for the occur-
rence of p53 mutations in the most aggressive and drug-
resistant AMLs.
Materials and methods
Retroviral constructs
LGmCreER was constructed in the MSCV backbone (Clontech)
using standard cloning techniques. We sequentially inserted
a GFP PCR product, a customized double-stranded oligonucleo-
tide containing a SalI/NsiI cloning site and two lox511 sites
(Hoess et al. 1986) flanking an MfeI/AvrII cloning site. The PGK
promoter and CreERT2 (Feil et al. 1997) were cloned by PCR
between the two lox511 sites. The empty miR30 context and
previously validated miR30-embedded shRNAs targeting firefly
luciferase (Silva et al. 2005) and mouse Trp53 (Dickins et al.
2005) were cloned into the SalI/NsiI site. In addition to ‘‘self-
deleting’’ LGmCreER harboring two lox511 sites flanking PGK-
CreERT2, we created a ‘‘non-self-deleting’’ version of LGmCreER
by removing the first lox511 site. The latter vector was used in
all experiments in which GFP-positive cells were traced for in
vitro proliferation, colony formation, stem/progenitor cells anal-
ysis, and sorting to ensure that GFP-positive cells uniformly
harbored both the shRNA and CreERT2 (typically, a minor frac-
tion of ‘‘self-deleting’’ LGmCreER virus does not carry PGK-
CreERT2 due to leaky Cre activity in packaging cells) (see
Supplemental Fig. S1 for details). MSCV-CreERT2-IRES-GFP
was cloned by PCR of CreERT2 into the MSCV-IRES-GFP
backbone (Clontech). The LMP vector has been described pre-
viously (Dickins et al. 2005).
Mouse strains
All mouse strain-related experiments were performed under the
approval of the Cold Spring Harbor Laboratory Animal Care and
Use Committee. LSL KrasG12D and Mx1-Cre mice (kind gifts
from Dr. Kevin Shannon, University of California at San Fran-
cisco) were backcrossed onto the C57BL/6 background for more
than six generations. Trp53loxp/loxp mice (Jonkers et al. 2001)
were backcrossed onto C57BL/6 for four generations before
generating quadruple Mx1-Cre;LSL-KrasG12D;p53loxp/loxp (CPK)
mice. Genotyping was performed according to standard pro-
tocols available at http://mouse.ncifcrf.gov. For induction of Cre
expression, mice of ;6 wk of age were injected i.p. with three
doses of 250 mg of pIpC (Sigma-Aldrich) every other day.
HSPC isolation, retroviral transduction, and transplantation
HSPCs were isolated from fetal livers (embryonic day 13.5–15.5),
cultured, and retrovirally transduced as described (Schmitt et al.
2002a), except that only early viral supernatant harvested from
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packaging cells 24, 30, and 36 h after transfection was used in
order to minimize leaky self-deletion of PGK-CreERT2. Retrovi-
ral transduction of GFP-expressing constructs was assessed 24 h
after the last infection by flow cytometry (Guava EasyCyte,
Guava Technologies). To induce Cre activity in vitro, infected
HSPCs were treated with 0.2 mM 4-OHT (Sigma-Aldrich; dis-
solved in 95% cold ethanol) for 36–48 h. Approximately 2 3 106
cells were injected into the tail vein of 8- to 10-wk-old lethally
irradiated syngeneic recipient mice (9.0 Gy total in two split
doses) (Gammacell 40 Exactor; MDS Nordion). To induce Cre
activity in vivo, 4 mg of 4-OHT (Sigma-Aldrich; emulsified at 40
mg/mL in sunflower seed oil by sonication) was administrated
i.p. for four consecutive days after reconstitution of recipient
mice. For secondary leukemia transplantation, 23 106 leukemia
cells freshly harvested from bone marrow were transplanted into
sublethally irradiated syngeneic recipient mice (4.5 Gy as single
dose).
HSPC proliferation and colony formation analysis and other
in vitro assays
LSL-KrasG12D and wild-type HSPCs were infected with a non-
self-deleting version of LGmCre vectors containing shluc or
shp53 and treated with 0.2 mM 4-OHT for 48 h. For the BrdU
assay, we used an APC BrdU Flow Kit (BD Pharmingen). BrdU
was added 2 h before analysis at a final concentration of 1 mM;
staining and analysis were carried out according to the manu-
facturer’s protocol. For methylcellulose colony formation, 5000
GFP-positive cells were plated into Methocult GF M3534 (Stem
Cell Technologies), cultured on 35-mm dishes, and imaged with
GFP fluorescence and bright-field phase-contrast optics of a Zeiss
Observer Z.1 inverted microscope. After 7 d of culture, images of
the entire surface were collected using a 53 objective, a Zeiss
MRm monochrome CCD camera, and Zeiss Axiovision 4.7.3
software, and were subsequently analyzed by ImageJ. Colonies
were harvested to repeat the same procedure for serial replating.
For STIFA culture, 2.5 3 106 transduced and 4-OHT-treated
HSPCs were transferred into 6 mL of STIFA medium (composi-
tion exactly as described in Akala et al. 2008); cytokines were
replenished every 3 d. Proliferation of stem and progenitor cells
was analyzed by flow cytometry. LSL-LacZ NIH-3T3 fibroblasts
(a kind gift from Ronald DePinho) were transduced with
LGmCreER and MSCV-CreERT2-IRES-GFP, treated with 0.5 mM
4-OHT for 72 h or left untreated, and subsequently stained using
the Stain for b-Gal Expression in Tissue kit (Millipore).
Histocytological and molecular characterization of leukemias
Peripheral blood smears (Wright-Giemsa-stained) of recipient
mice were monitored starting from 4 wk after transplantation.
Ultrasonic imaging was performed 7 wk after transplantation
using a Vevo 770 Imaging System (Visualsonics). Fluorescence-
based whole-body GFP imaging was performed using an Illuma-
tool LT-9900 Bright Light System (LightTools, Optical Research)
as described (Schmitt et al. 2002b). Animals were sacrificed by
CO2 euthanasia upon severe leukocytosis and/or moribund
appearance. Statistical evaluation of overall survival was based
on the log-rank (Mantel-Cox) test for comparison of the Kaplan-
Meier event time format. Organs were fixed in 10% neutral
buffered formalin and were processed to obtain paraffin sections
for histological staining. Bone marrow cells were flushed from
tibias and femurs with PBS with 2% FBS. Erythrocytes were
lysed in ACK (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA)
for 5 min.; nucleated cells were resuspended in PBS/2% FBS and
filtered through a nylon screen (100 mm) to obtain a single-cell
suspension. Whole bone marrow cells were stained with PE-
conjugated antibodies for Sca1, cKit, CD34, Mac1, Gr1, B220,
Thy1, and Ter119 (BD Biosciences) for single staining. Data were
collected on an LSR-II flow cytometer (BD Biosciences), and were
analyzed using FACSDiva (BD Biosciences) and FlowJo (Treestar)
software.
Flow cytometry analysis and FACS
For flow cytometry analysis of phosphorylated Ras effectors,
bone marrow cells were harvested from femurs and tibias into
IMDM containing 1% BSA (Sigma). Erythrocytes were lysed
(ACK), and mononuclear cells were incubated in harvesting
medium for 45 min at 37°C. For growth factor stimulation, cells
were incubated with 10 ng/mL murine GM-CSF (Invitrogen) for
15min prior to fixation. Antibodies and experimental procedures
were exactly as described previously (Van Meter et al. 2007). For
stem and progenitor analysis and sorting, we used lineage
markers (Mac1, Gr1, CD3, CD4, CD8, B220, and Ter119), Sca1,
cKit, IL-7R, CD150, and CD48. Antibodies were conjugated
directly or biotinylated and purchased from e-Bioscience, BD
Biosciences, and BioLegend; cells were analyzed and sorted on an
Aria-II cell sorter (BD Biosciences). HSCs, MPPs, and myeloid
progenitors were identified as CD150+CD48Sca1+LincKit+,
CD150CD48Sca1+LincKit+, andcKit+Sca1LinIL-7Rapop-
ulations, respectively (Kiel et al. 2005; Kim et al. 2006; Akala
et al. 2008). For mosaic transplantation recipients, only GFP-
positive HSCs or myeloid progenitors were sorted. All HSCs and
myeloid progenitors were doubly sorted into PBS, and were
transplanted by retro-orbital venous sinus injection into B6/SJL
(Ly5.1) mice lethally irradiated with 8.2 Gy (single dose), together
with a radioprotective dose of 2 3 105 C57BL/6 bone marrow
cells.
PCR analysis of Cre-mediated recombination
To assess Cre-mediated recombination of the LSL cassette in
vivo, genomic DNAwas extracted from peripheral blood prior to
and after 4-OHT treatment, as well as from bone marrow and
spleen of diseased mice. To detect recombination events with
high sensitivity, we designed a two-step allele-specific PCR
(Supplemental Fig. S3). For the first step, we used primers
flanking the remaining loxP site (KLSLfw3, 59-AAGCAAGGCA
GAAGTCACAGAGG-39; LoxedRasRv, 59-TCCGAATTCAGTG
ACTACAGATGTACAGAG-39) and amplified as follows: ini-
tially at 95°C for 10 min; 34 cycles of 95°C for 30 sec, 64°C for
45 sec, and 72°C for 60 sec; and ending with 72°C for 7 min,
yielding products of 709 and 749 base pairs (bp) for wild-type and
recombined alleles, respectively. To sensitively detect recom-
bined alleles even in small cellular subfractions (e.g., peripheral
blood), a 1:100 dilution of the primary PCR products was used in
a secondary PCR using a nested primer set specifically amplify-
ing alleles harboring a single remaining loxP site (KLSLfw4,
59-GTGCAGTTTTGACACCAGCTTCG-39; KLSLrev4, 59-CGC
ATGAGCTTGTCGACATAACTTCG-39) with the following cy-
cling: initially at 95°C for 10 min; 28 cycles of 95°C for 30 sec,
65°C for 30 sec, and 72°C for 60 sec; and ending with 72°C for
7 min.
Immunoblotting and Southern blotting analysis
Wild-type MEFs were infected with LMPmir30, LMPshp53,
LGmCreER, and LGshp53CreER. Infection efficiencies were
>95%, indicated by GFP percentage analyzed 48 h post-infection.
Infected cells were incubated with or without 0.5 mM 4-OHT for
48 h. Bone marrow cells were harvested as above from wild-type,
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Kras-shp53 leukemic, and p53/ and p19Arf/ control leuke-
mic mice. Control leukemias were generated by transduction of
MLL/ENL into p53/ and p19Arf/ HSPCs as described pre-
viously (Zuber et al. 2009). To induce p53, all samples were
treated with 1 mg/mL adriamycin for 5 h and then harvested for
whole-cell lysates. p53 immunoblotting was performed as de-
scribed previously (Hemann et al. 2003). Genomic DNA was
isolated from infected untreated or 4-OHT-treated (0.5 mM, 4 d)
MEFs and packaging cells at different time points after trans-
fection. Southern blotting of NheI-digested DNAwas performed
using standard techniques. Hybridization was performed in
CHURCH buffer (0.25 M sodium phosphate buffer at pH 7.2,
1 mM EDTA, 1% BSA, 7% SDS) under addition of 100 mg/mL
sonicated sperm DNA using a PCR-amplified GFP probe la-
beled with aP32-dATP (Megaprime DNA labeling system,
Amersham).
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